Frontlight ResearchEarly access
Not yet recruitingPhase 4
Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism
Key facts
- Who runs it
- Region Midtjylland
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 1 Feb 2026
- Expected to end
- 31 Jan 2028
- Type of study
- Interventional
- Record updated
- 20 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Male or female with age between 18 and 80 years
- A low endogenous PTH production is verified by low plasma levels of intact PTH, necessitating treatment with 1-αhydroxylated vitamin D analogs
- Stable P-calcium levels 1 month prior to inclusion
- Stable thyroid function as measured by thyroid stimulating hormone (TSH)
- Speaks and reads Danish
Who cannot take part
- Metal implants close to the head, which will interfere with the MRI or pacemaker. The patients will complete a metal scheme
- Uncontrolled diabetes type 1 or 2
- Uncontrolled hypertension
- Clinical suspicion of ongoing alcohol abuse (or alcohol-related dementia)
- Other organic or psychiatric cause the patients’ symptoms
- Reduced kidney function (eGFR < 30 mL/min/1.73m2)
- Claustrophobia
- Pregnancy
- Unwillingness to participate
- Clinical suspicion of major depression (also if treated)
- Contraindications to contrast-enhanced MRI
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
We would like to compare patients with chronic HypoPT treated with TransCon for a long-time period with chronic HypoPT patients treated with conventional treatment (activated vitamin D analogue and calcium supplements) to investigate whether the effect of HypoPT on QoL, neuropsychiatric indices, brain structures, and capillary blood flow are reversed with PTH treatment. We will apply our contrast-enhanced MRI based method to examine whether differences in brain structure and capillary dysfunction depends on the treatment used.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 20 April 2026